These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 1857337)
21. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein. Hatzelmann A; Goossens J; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R Biochem Pharmacol; 1994 Jun; 47(12):2259-68. PubMed ID: 8031320 [TBL] [Abstract][Full Text] [Related]
22. Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase. Gupta N; Nicholson DW; Ford-Hutchinson AW Can J Physiol Pharmacol; 1997; 75(10-11):1212-9. PubMed ID: 9431445 [TBL] [Abstract][Full Text] [Related]
23. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Dixon RA; Diehl RE; Opas E; Rands E; Vickers PJ; Evans JF; Gillard JW; Miller DK Nature; 1990 Jan; 343(6255):282-4. PubMed ID: 2300173 [TBL] [Abstract][Full Text] [Related]
25. Pharmacological modulation of human platelet leukotriene C4-synthase. Sala A; Folco G; Henson PM; Murphy RC Biochem Pharmacol; 1997 Mar; 53(6):905-8. PubMed ID: 9113110 [TBL] [Abstract][Full Text] [Related]
26. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Evans JF; Ferguson AD; Mosley RT; Hutchinson JH Trends Pharmacol Sci; 2008 Feb; 29(2):72-8. PubMed ID: 18187210 [TBL] [Abstract][Full Text] [Related]
27. Effect of FLAP antagonist MK-0591 on leukotriene production and ozone-induced airway responses in dogs. Stevens WH; Lane CG; Woolley MJ; Ellis R; Tagari P; Black C; Ford-Hutchinson A; O'Byrne PM J Appl Physiol (1985); 1994 Apr; 76(4):1583-8. PubMed ID: 8045835 [TBL] [Abstract][Full Text] [Related]
28. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds. Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R Biochem Pharmacol; 1993 Jan; 45(1):101-11. PubMed ID: 8381000 [TBL] [Abstract][Full Text] [Related]
29. Regulation of the production and action of leukotrienes by MK-571 and MK-886. Ford-Hutchinson AW Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():9-16. PubMed ID: 1847788 [No Abstract] [Full Text] [Related]
30. Expression, purification and crystallization of human 5-lipoxygenase-activating protein with leukotriene-biosynthesis inhibitors. Xu S; McKeever BM; Wisniewski D; Miller DK; Spencer RH; Chu L; Ujjainwalla F; Yamin TT; Evans JF; Becker JW; Ferguson AD Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Dec; 63(Pt 12):1054-7. PubMed ID: 18084092 [TBL] [Abstract][Full Text] [Related]
31. Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591. Tagari P; Becker A; Brideau C; Frenette R; Sadl V; Thomas E; Vickers P; Ford-Hutchinson A J Pharmacol Exp Ther; 1993 Apr; 265(1):416-25. PubMed ID: 8386242 [TBL] [Abstract][Full Text] [Related]
32. Increases in 5-lipoxygenase activating protein expression account for enhanced capacity for 5-lipoxygenase metabolism that accompanies differentiation of peripheral blood monocytes into alveolar macrophages. Coffey MJ; Wilcoxen SE; Peters-Golden M Am J Respir Cell Mol Biol; 1994 Aug; 11(2):153-8. PubMed ID: 8049076 [TBL] [Abstract][Full Text] [Related]
33. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. Rouzer CA; Ford-Hutchinson AW; Morton HE; Gillard JW J Biol Chem; 1990 Jan; 265(3):1436-42. PubMed ID: 2104841 [TBL] [Abstract][Full Text] [Related]
34. 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP). Banoglu E; Çelikoğlu E; Völker S; Olgaç A; Gerstmeier J; Garscha U; Çalışkan B; Schubert US; Carotti A; Macchiarulo A; Werz O Eur J Med Chem; 2016 May; 113():1-10. PubMed ID: 26922224 [TBL] [Abstract][Full Text] [Related]
35. Identification and isolation of a membrane protein necessary for leukotriene production. Miller DK; Gillard JW; Vickers PJ; Sadowski S; Léveillé C; Mancini JA; Charleson P; Dixon RA; Ford-Hutchinson AW; Fortin R Nature; 1990 Jan; 343(6255):278-81. PubMed ID: 2300172 [TBL] [Abstract][Full Text] [Related]
36. Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein. Macdonald D; Brideau C; Chan CC; Falgueyret JP; Frenette R; Guay J; Hutchinson JH; Perrier H; Prasit P; Riendeau D; Tagari P; Thérien M; Young RN; Girard Y Bioorg Med Chem Lett; 2008 Mar; 18(6):2023-7. PubMed ID: 18276139 [TBL] [Abstract][Full Text] [Related]
37. FLAP inhibitors for the treatment of inflammatory diseases. Sampson AP Curr Opin Investig Drugs; 2009 Nov; 10(11):1163-72. PubMed ID: 19876784 [TBL] [Abstract][Full Text] [Related]
38. 5-Lipoxygenase activating protein (FLAP) dependent leukotriene biosynthesis inhibition (MK591) attenuates Lipid A endotoxin-induced inflammation. Fang WF; Douglas IS; Wang CC; Kao HC; Chang YT; Tseng CC; Huang KT; Chang HC; Lin MC PLoS One; 2014; 9(7):e102622. PubMed ID: 25025775 [TBL] [Abstract][Full Text] [Related]
39. 5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis. Plante H; Picard S; Mancini J; Borgeat P Biochem J; 2006 Jan; 393(Pt 1):211-8. PubMed ID: 16144515 [TBL] [Abstract][Full Text] [Related]
40. 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. Woods JW; Evans JF; Ethier D; Scott S; Vickers PJ; Hearn L; Heibein JA; Charleson S; Singer II J Exp Med; 1993 Dec; 178(6):1935-46. PubMed ID: 8245774 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]